Compare Ascendis Pharma A/S (ASND) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Riot Platforms Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Riot Platforms Inc trades at $20.71 (market cap $7.93B). The key difference: Ascendis Pharma A/S is far larger — about 2.2× Riot Platforms Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Riot Platforms Inc nearer its low. Which is the better fit depends on your goals.
| ASND | RIOT | |
|---|---|---|
Market Cap | $17.74B | $7.93B |
Sector | Health | Technology |
52-Week High | $277.18 | $28.67 |
52-Week Low | $163.32 | $11.03 |
Enterprise Value | $18.11B | $8.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
RIOT trades at $20.97, down 2.58% today, with a bearish technical signal. Recent earnings show mixed results, beating in Q3 2025 but missing in Q4 2025 and Q1 2026. The company reported a net loss of $663 million in 2025 despite $647 million revenue. Analyst consensus is strongly bullish with a $27.86 price target. News highlights volatility tied to Bitcoin trends and a strategic pivot toward AI data centers.
Outlook remains speculative with high valuation multiples amid persistent losses. Opportunities include expansion into high-performance computing, but risks involve cash flow deficits, competitive pressures, and sensitivity to cryptocurrency markets. Investors should weigh analyst optimism against fundamental challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
